Arbutus Biopharma Corp Live Stock Price Today, Share Analysis and Chart

Name: Arbutus Biopharma Corp: Is Infosys Ltd. worth buying?
Item: Arbutus Biopharma Corp
Rating: 1.98470825
Author: Trendlyne DVM scores

Await Turnaround

about

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can b...

4.41 0.12 (2.80%)

35.28% Gain from 52W Low

786.2K

XNAS Volume

XNAS 30 Jul, 2026 5:30 PM (EDT)

Board Meeting

The next board meeting for Arbutus Biopharma Corp is on 06 Aug 2026 for the purpose of Arbutus Biopharma Corp Second Quarter Earnings Results for 2026 See details

Low Financial Strength

33.3 / 100

Mid Valuation

48.0 / 100

Technically Neutral

44.1 / 100

Await Turnaround These stocks have poor financials and average valuation and momentum. Investors should be cautious about these stocks View Similar Embed DVM

1Yr Price target upside is 17%

2 analysts

Arbutus Biopharma Corp Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Arbutus Biopharma Corp Live Stock Price Today, Share Analysis and Chart

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can b...

35.28% Gain from 52W Low

SWOT Analysis

Arbutus Biopharma Corp Live Price Chart

Arbutus Biopharma Corp Live Price Chart